DUBLIN, Ireland, and Boston, MA, February 28, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announced it has…Original Article
Amryt Receives Complete Response Letter from the FDA for Oleogel-S10 NDA
